The QuadShot heard ‘round the world.

For rad onc residents, it’s that time of year. Time for the annual in-service exam, which means shots--QuadShots--the most shots you've seen since Cancun ‘06. Cheers. CNS | In CATNON, TMZ improves 5y OS for non-codeleted gliomas (44v55%). For GBM, consolidative TTF improves OS (16v21mo), and adding TMZ to 40 Gy / 15 improves OS for old people (7v9mo). For mets, delaying SRS to give EGFR agents reduces survival. For post-op mets, LC is improved with SRS v obs (72v43%) and with WBRT+/-SRS v SRS alone (81v61%). In QUARTZ, WBRT is no better than BSC for non-SRS candidates. Breast | In 10y outcomes of Z0011, SLND remained noninferior to ALND for OS (86 v 84%) and DFS (80 v 78%) with only 1v0 regional recurrences at 5-10y. Melanoma | For stage III/IV, either BRAF or nivo+/-ipi improves RFS 10-20%. In MSLT-II, completion LND improved nodal control (77v92%) but not the 1° endpoint of OS. Lung | [NSCLC] In PACIFIC, durvalumab after chemoRT improves PFS (6v17mo). There’s no difference in pneumonitis or local failure between photons v protons. SABR to oligomets improves PFS (3.5v10mo). In ADJUVANT, post-op gefitinib for pN+ improves DFS (18v29mo). [SCLC] In CONVERT, 66 Gy daily was NOT superior to 45 Gy BID. HNSCC | cECE is now N3 for HPV(-) OPX, and mets are necessary to be stage IV for HPV(+) OPX. Concurrent cisplatin q1wk has lower 2y LRC than q3wk (72v85%). Number of nodes (not size or laterality) predict survival for larynx/hypoPX. In MARCH-HPV,HPV(+) has no special benefit from altered fx. Prostate | 24mo of bicalutamide with salvage RT improves 12y rates of OS (71v76%), prostate cancer death (13v6%), and mets (23v14.5%). Post-op endometrial | In GOG 258, there was no difference in RFS for stage III/IVA with chemo v chemoRT. In GOG 249, there was no difference in RFS at 3y (82%) for HIR with pelvic RT v chemo + brachy. In PORTEC 3, stage III (RFS) and pts ≥70 (OS) benefited from addition of chemo to pelvic RT. GI | Peri-op FLOT is the new standard for gastric cancer, and adding cetuximab to chemoRT for esophageal cancer improves nothing. But who are we kidding, hope you brushed up on ESPAC data.


Popular Posts